Connect with us

Business

Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant – ABC News

The success of Pfizer’s mRNA-based COVID vaccine looks set to secure the company a multi-billion-dollar windfall for many years as countries already start booking…

Published

on

Article feature image

The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.
Key points:

  • Pfizer has raised its 2021 revenue forecasts for COVID vaccine sales by 73 per cent
  • The company is hoping to ramp up production to 2.5 billion doses this year and three billion in 2022
  • Pfizer is evaluating a prototype to include the South African variant and expects annual flu-style vaccinations…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

2 top ASX growth shares rated as buys in May
2 small cap ASX shares that are growing quickly Sunday 16 May 2021